This is Almirall's legacy for future generations, it is our contribution to society.
We have a firm commitment to focusing our R&D on key therapeutic areas. Our efforts cover the whole value chain for medication. Our consolidated growth in talent and expertise ensures our positioning as a global reference in skincare.
40 years of developing treatments to make a difference to people’s lives. By adding our own expertise to our international partners, we build solutions for today and tomorrow’s needs.
Leadership in dermatology
Our recent powerful shift in focus towards and becoming a key player in medical dermatology can be seen by both organic and acquired growth. Innovation in other areas ensures key product success.
Leadership in dermatology
R&D - therapeutical areas: Derma
We are driven by science, diligent by nature. Our medicines help to make a significant difference to patients’ lives by treating a wide of range of skin diseases.
A global company close at hand
Almirall has consolidated international coverage on a global scale thanks to owned subsidiaries and sales agreements with the most prestigious partners in key markets such as the USA, Japan and China.
13Affiliates in EU & US
21Countries with direct presence
70Countries with partnership agreements
Our global presence
We are where you need us to be
Our extensive product portfolio is available in more than 70 countries – either through the 13 owned-subsidiaries or via the network of strategic partnerships that we have developed over time. Our focus is global and since our beginnings we have grown our coverage to be where you need us to be.
General Mitre, 151
08022 Barcelona - España
+34 93 291 30 00
707 Eagleview Boulevard,
19341 Exton, PA
Almirall Sp. z o.o.
Ul Pileckiego 63
+48- 22 330 0257
Almirall - Produtos Farmacêuticos, Lda.
Rua do Central Park
Edificio 3, numero 6, 4B
2795-242 Linda A Velha
+351 214 155750
Via Messina, 38 Torre C
20154 - Milano
+39 02 34 618 1
Alte Winterthurerstrasse 14
+41 (0) 44 834 9000
Siège Almirall, SAS
Immeuble Le Barjac
1, boulevard Victor
+33 01 46 46 19 20
1 George St
Middlesex UB8 1QQ
+44 (0)20 7160 2500
+32 2 771 86 37
3528 BJ Papendorp
+31 - 30 799 1155
Almirall Hermal GmbH
+49 (0) 40 727 04-0
Breitenfurter Str. 113, Top 101
+43 (0) 1 595 39 60
Almirall’s Leadership and Governance
As a publicly listed company and for the benefit of both the financial markets and the general public, Almirall pursues an open and active information policy.
Almirall has been Caring for people since 1943
Our company was founded in Barcelona
We develop and launched a leading antacid treatment
We progress in the field of antihistamics in Spain and we started licencing our products internationally.
We obtain the U.S. Food and Drug Administration (FDA) approval for an own R&D antimigraine treatment.
We acquired Hermal, a European skincare business previously owned by Reckitt Benckiser.
Aqua Pharmaceuticals, a North American skincare company, was acquired.
We continued our acquisition strategy in skincare by buying Poli Group, world leader in nail and skin diseases.
In June of that year, the European Commission approved a new Fumaric Acid Ester of our own R&D to treat psoriasis. In December, same year, we announced a collaboration agreement to develop a treatment for actinic keratosis and other skin conditions, both in Europe and the USA.
In January of that year, our US subsidiary announced the launch of the first antibiotic treatment specifically developed for acne. We also obtained the rights for developing a humanized monoclonal antibody in Europe for the treatment of atopic dermatitis.
We began activities in research and development
We became the Pharmaceutical Industry Spanish market leader
We created Almirall Prodesfarma Laboratories as a result of the merger between Almirall and Prodesfarma Pharmaceutical Groups.
We gained the commercial rights for distributing a cannabinoid based medicine in Europe, for patients with Multiple Sclerosis.
The EMA and the FDA approves the commercialization of Almirall's bronchodilator for the treatment of chronic obstructive pulmonary disease (COPD) in Europe and the USA.
We transferred the rights for our respiratory franchise to the AstraZeneca company.
Sun Pharmaceutical Industries signed an agreement with us to develop and commercialise a new biological treatment for psoriasis in Europe.
We reached an agreement with Allergan to acquire five products from their US skincare business to treat acne and dermatosis.
Almirall is committed to working with you on a basis of respect and integrity. We understand there are many people affected by what we do, including patients, healthcare professionals, our partners, peers and other stakeholders.Learn more about our commitments
You might be interested in...
Focus on medical needs. Provide treatment solutions for both today’s and future generations.
Almirall discloses its support to patient organizations in accordance with the EFPIA Code of Practice.